Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin

32Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Declining nicotinamide adenine dinucleotide (NAD+) concentration in the brain during aging contributes to metabolic and cellular dysfunction and is implicated in the pathogenesis of aging-associated neurological disorders. Experimental therapies aimed at boosting brain NAD+ levels normalize several neurodegenerative phenotypes in animal models, motivating their clinical translation. Dietary intake of NAD+ precursors, such as nicotinamide riboside (NR), is a safe and effective avenue for augmenting NAD+ levels in peripheral tissues in humans, yet evidence supporting their ability to raise NAD+ levels in the brain or engage neurodegenerative disease pathways is lacking. Here, we studied biomarkers in plasma extracellular vesicles enriched for neuronal origin (NEVs) from 22 healthy older adults who participated in a randomized, placebo-controlled crossover trial (NCT02921659) of oral NR supplementation (500 mg, 2x /day, 6 weeks). We demonstrate that oral NR supplementation increases NAD+ levels in NEVs and decreases NEV levels of Aβ42, pJNK, and pERK1/2 (kinases involved in insulin resistance and neuroinflammatory pathways). In addition, changes in NAD(H) correlated with changes in canonical insulin–Akt signaling proteins and changes in pERK1/2 and pJNK. These findings support the ability of orally administered NR to augment neuronal NAD+ levels and modify biomarkers related to neurodegenerative pathology in humans. Furthermore, NEVs offer a new blood-based window into monitoring the physiologic response of NR in the brain.

References Powered by Scopus

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines

7750Citations
N/AReaders
Get full text

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease

1171Citations
N/AReaders
Get full text

Nicotinamide mononucleotide, a key NAD <sup>+</sup> intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

1068Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Human trials exploring anti-aging medicines

49Citations
N/AReaders
Get full text

What is really known about the effects of nicotinamide riboside supplementation in humans

31Citations
N/AReaders
Get full text

The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update

25Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Vreones, M., Mustapic, M., Moaddel, R., Pucha, K. A., Lovett, J., Seals, D. R., … Martens, C. R. (2023). Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell, 22(1). https://doi.org/10.1111/acel.13754

Readers over time

‘23‘24‘2509182736

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

59%

Professor / Associate Prof. 6

27%

Researcher 3

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

32%

Agricultural and Biological Sciences 5

26%

Biochemistry, Genetics and Molecular Bi... 5

26%

Neuroscience 3

16%

Article Metrics

Tooltip
Mentions
Blog Mentions: 6
News Mentions: 47

Save time finding and organizing research with Mendeley

Sign up for free
0